• Careers
  • Investors
  • Contact
23andme-logo
  • About
  • Our Platform
  • Pipeline & Programs
    • Pipeline OverviewSee the 23andMe Therapeutics pipeline in full
    • 23ME-00610Clinical-stage therapeutic antibody designed to restore the immune system’s ability to kill cancer cells
    • 23ME-01473Clinical-stage antibody targeting ULBP6 to induce immune activation through dual mechanisms that may restore anti-tumor immunity.
  • Collaborations
  • News & Research
  • About Us
  • Our Platform
  • Pipeline & Programs
    • Overview
    • 23ME-00610
    • 23ME-01473
  • Collaborations
  • News & Research
  • Careers
  • Contact
  • Investors
logo-footer

SERVICES

  • Health + Ancestry
  • Ancestry Service
  • 23andMe+ Premium
  • 23andMe+ Total Health
  • Gifts

COMPANY

  • Investors
  • About Us
  • Diversity, Equity, & Inclusion
  • Media Center
  • Blog
  • Genetics Learning Hub
  • Careers
  • Refer a Friend
  • Return Policy
  • Customer Care
  • FSA/HSA Eligibility

LEGAL

  • Important Test Info
  • Terms of Service
  • Privacy Statement
  • Data Protection
  • Family Considerations
  • Research Consent
  • Individual Data Consent
  • Biobanking Consent
  • Cookie Policy
  • Cookie Choices
  • Patent Information
  • Report a Security Issue
  • Consumer Health Data Privacy Policy

PARTNER WITH US

  • Healthcare Professionals
  • Education
  • Scientists
  • Therapeutics

DOWNLOAD APP

apple-store
google-play

DOWNLOAD APP

apple-store
google-play

©2024 23andMe, Inc. All rights reserved.

RECENT NEWS

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

Learn more

RECENT NEWS

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

Learn more

RECENT NEWS

Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell...

Learn more

RECENT NEWS

Phase 1/2a trial of CD200R1 inhibitor 23ME-00610: exploratory analyses of tissue-based and genetic biomarkers

Learn more

RECENT NEWS

23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcγRIIIa activation

Learn more

RECENT NEWS

A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody, for Patients with Advanced Solid Malignancies

Learn more

RECENT NEWS

Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or micro...

Learn more